Literature DB >> 30938923

Clinicopathological predictors of occult lateral neck lymph node metastasis in papillary thyroid cancer: A meta-analysis.

Shaohua Zhan1, Dan Luo1, Wei Ge1, Bin Zhang2, Tianxiao Wang2.   

Abstract

BACKGROUND: This meta-analysis aimed to identify the clinicopathological factors that could predict the risk of occult lateral neck lymph node metastasis (OLLNM) in N0/N1a papillary thyroid cancer (PTC).
METHODS: A literature search of PubMed, Web of Science, OvidSP, and Chinese National Knowledge Infrastructure databases was performed using relevant keywords. Specific odds ratios and confidence intervals were calculated.
RESULTS: The final analysis included 15 studies with a total of 5342 patients. OLLNM was found to be significantly associated with some clinicopathological features, including age <45 years, male sex, extrathyroidal extension, tumor location in the upper pole, tumor size >10 mm, positive central lymph node metastasis, number of central lymph node metastasis ≥3, and vascular invasion.
CONCLUSIONS: Fine-needle aspiration (FNA) cytology or FNA-Tg test might be an appropriate and reasonable intervention in the patients with N0/N1a PTC with an increased risk of OLLNM.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  fine-needle aspiration; meta-analysis; occult lateral neck lymph node metastasis; papillary thyroid cancer; pathological features

Year:  2019        PMID: 30938923     DOI: 10.1002/hed.25762

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  9 in total

1.  A retrospective study of the risk factors and the prognosis in patients with papillary thyroid carcinoma depending on the number of lymph node metastasis.

Authors:  Zhong Ying Rui; Yang Liu; Wei Zheng; Xuan Wang; Zhao Wei Meng; Jian Tan; Ning Li; Qiang Jia
Journal:  Clin Exp Med       Date:  2021-01-01       Impact factor: 3.984

2.  Relationship between subgroups of central and lateral lymph node metastasis in clinically node-negative papillary thyroid carcinoma.

Authors:  Jing Zhou; Da-Xue Li; Han Gao; Xin-Liang Su
Journal:  World J Clin Cases       Date:  2022-04-26       Impact factor: 1.534

3.  [Effects of RNA interference of CTHRC1 on proliferation and apoptosis of thyroid papillary cancer TCP-1 cells in vitro].

Authors:  Z Tang; X Ding; S Qin; C Zhang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-04-20

4.  Analysis of Risk Factors of Level V Lymphatic Metastasis for Papillary Thyroid Carcinoma with pN1b.

Authors:  Chuang Li; Zhao-Zhong Meng; Jian-Wu Qin; Xin-Guang Qiu
Journal:  J Oncol       Date:  2021-08-18       Impact factor: 4.375

5.  Male Gender Is Associated with Lymph Node Metastasis but Not with Recurrence in Papillary Thyroid Carcinoma.

Authors:  Jiang Zhu; Rui Huang; Ping Yu; Haoyu Ren; Xinliang Su
Journal:  Int J Endocrinol       Date:  2022-02-28       Impact factor: 3.257

6.  Nomograms for the prediction of lateral lymph node metastasis in papillary thyroid carcinoma: Stratification by size.

Authors:  Jia-Wei Feng; Jing Ye; Li-Zhao Hong; Jun Hu; Fei Wang; Sheng-Yong Liu; Yong Jiang; Zhen Qu
Journal:  Front Oncol       Date:  2022-09-28       Impact factor: 5.738

7.  Lateral neck multilevel fine-needle aspiration cytology and thyroglobulin estimation in papillary thyroid carcinoma.

Authors:  Yuntao Song; Guohui Xu; Tianxiao Wang; Bin Zhang
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-05-25

8.  Risk Factors and Prediction Model for Lateral Lymph Node Metastasis of Papillary Thyroid Carcinoma in Children and Adolescents.

Authors:  Weili Liang; Lei Sheng; Liguang Zhou; Changyuan Ding; Zhongyang Yao; Chao Gao; Qingdong Zeng; Bo Chen
Journal:  Cancer Manag Res       Date:  2021-02-16       Impact factor: 3.989

9.  Lateral Lymph Node Metastases in T1a Papillary Thyroid Carcinoma: Stratification by Tumor Location and Size.

Authors:  Xiaojun Zhang; Wenkuan Chen; Qigen Fang; Jie Fan; Lu Feng; Lanwei Guo; Shanting Liu; Hong Ge; Wei Du
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-15       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.